Amneal Pharmaceuticals (AMRX) Intangibles (2017 - 2026)

Amneal Pharmaceuticals' Intangibles history runs 10 years deep, the most recent figure standing at $534.9 million for Q1 2026.

• On a quarterly basis, Intangibles fell 22.39% year-over-year to $534.9 million in Q1 2026; TTM through Mar 2026 was $534.9 million, a 22.39% decrease from a year earlier, with the FY2025 full-year figure at $563.5 million, down 23.06% from the prior year.
• Intangibles fell to $534.9 million in Q1 2026 per AMRX's latest filing, from $563.5 million in the prior quarter.
• Across five years, Intangibles topped out at $1.2 billion in Q1 2022 and bottomed at $534.9 million in Q1 2026.
• The 5-year median for Intangibles is $859.3 million (2024), against an average of $872.3 million.
• Across the five-year window, Intangibles declined 4.21% in 2022 and decreased 24.64% in 2025, its largest moves.
• Year by year, Intangibles stood at $1.1 billion in 2022, then declined by 18.76% to $890.4 million in 2023, then decreased by 17.75% to $732.4 million in 2024, then dropped by 23.06% to $563.5 million in 2025, then declined by 5.08% to $534.9 million in 2026.
• Per Business Quant, the three latest AMRX Intangibles figures stand at $534.9 million (Q1 2026), $563.5 million (Q4 2025), and $587.9 million (Q3 2025).